The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

but Saxenda is a higher dose. Although the target for each formulation is the same (the GLP-1 receptor), for glucose control in type 2 diabetes, liraglutide has to (mainly) reach the pancreas.

which are sold under the brand names Saxenda and Wegovy. Nearly 1 in 3 patients halted treatment within four weeks, before the recommended dosage reached the drugs' targeted strength. Because ...

The NICE recommendation coincided with Novo Nordisk’s third quarter results statement, which showed modest 3% growth for Saxenda in the first nine months of the year to DKK 4.2 billion ($661 ...

In the new SCALE Kids study, which has been published in the New England Journal of Medicine, a daily 3mg dose of Saxenda reduced the body mass index (BMI) of the children by an average of 5.8% ...

Saxenda and Wegovy are approved and licensed ... to help control blood sugar as well as weight but contains a lower dose of the same medicine, semaglutide, as Wegovy. And with some people without ...

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management, Biocon Ltd said in a regulatory filing. Also read: Has ...